U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Emergency Preparedness and Response
  3. Public Health Preparedness and Response
  4. Medical Countermeasures (MCMs)
  5. Medical Countermeasure Collaborations
  6. FDA Centers and Offices Supporting MCM Activities
  1. Medical Countermeasure Collaborations

FDA Centers and Offices Supporting MCM Activities

Image
Image representing MCMi collaborations between FDA centers and offices

The FDA coordinates medical countermeasure development, preparedness and response. This includes funding intramural research, and working with multiple FDA centers and offices to help ensure that U.S. laws, regulations, and policies support preparedness and response for potential chemical, biological, radiological and nuclear (CBRN) and emerging infectious disease threats. 

FDA centers and offices supporting MCM activities include, but are not limited to:

Center for Biologics Evaluation and Research (CBER)

CBER oversees the safety, effectiveness, quality, and availability of biological products, including vaccines, cells, tissues, and the blood supply. CBER collaborates in facilitating product development, manufacturing, and quality for needed CBRN MCMs.

Center for Drug Evaluation and Research (CDER)

CDER ensures that safe and effective drugs are available for preventing and treating illnesses from exposure to CBRN agents. CDER facilitates new drug development and new uses for already-approved drugs that could be used as MCMs.     

Center for Devices and Radiological Health (CDRH)

CDRH ensures that safe and effective diagnostics and personal protective equipment are available for diagnosing and preventing illnesses from exposure to CBRN agents, and ensures that radiation-emitting products meet radiation safety standards.

Center for Veterinary Medicine (CVM)

CVM ensures that animal drugs, food additives, devices, and medicated feeds are safe and effective, and makes certain that animal-based food is safe.

Human Foods Program (HFP)

HFP protects the nation's food supply from CBRN agent contamination and prevents suspect food imports from being distributed.     

National Center for Toxicological Research (NCTR)

NCTR conducts scientific research related to CBRN threats, including identifying virulent biomarkers, technologies for intervention, and rapid, “field-rugged” tests that can help detect bioterrorism agents.

Office of the Chief Medical Officer (OCMO)

OCMO supports medical product development and availability, promote patient and consumer health and advance innovative clinical research.

Office of the Chief Scientist (OCS)

OCS supports the research foundation, science, and innovation that underpins FDA’s regulatory mission through a broad framework that encompasses scientific collaborations, laboratory safety, the transfer of FDA inventions to the private sector, scientific integrity in FDA policy- and decision-making, professional development, and research to generate the vital data FDA requires for regulatory decision-making and development of sound regulatory policy. 

Office of Global Policy and Strategy (OGPS)

OGPS serves as the primary liaison with other U.S. government components, international and foreign governments for policy formulation and execution impacting FDA and FDA-regulated products.

Office of Inspections and Investigations (OII)

OII is the lead office for all FDA field inspection, investigation, import and emergency response related activities.

Office of Minority Health and Health Equity (OMHHE)

OMHHE serves to promote and protect the health of diverse populations through research and communication of science that addresses health disparities.

Office of Public Health Preparedness and Response (OPHPR)

OPHPR, in the OCMO, provides leadership, coordination, and oversight for the FDA’s national and global public health preparedness and response portfolios including consumer safety reporting, health emergencies, and medical product and critical food shortages and applicable supply chain issues.

Office of Women’s Health (OWH)

OWH promotes the inclusion of women in clinical trials and the implementation of guidelines concerning the representation of women in clinical trials and the completion of sex/gender analysis. 

Office of Regulatory and Emerging Science (ORES)

ORES furthers regulatory science, training, and engagement that supports the application of advances in science and technology to the development, viability, availability, and sustainability of FDA-regulated products. . 

Contact us

For product-specific questions, please contact the appropriate FDA center or office. Have a general MCMi-related question? Email us: AskMCMi@fda.hhs.gov. 

Subscribe

Sign up to receive email alerts on public health emergency preparedness and response topics from the FDA, including medical countermeasures and emerging infectious diseases.

Back to Top